Sensus Healthcare (NASDAQ:SRTS) Issues Earnings Results, Misses Expectations By $0.01 EPS

Sensus Healthcare (NASDAQ:SRTS) released its quarterly earnings data on Wednesday. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01), Zacks reports. Sensus Healthcare had a net margin of 22.54% and a return on equity of 17.99%.

Sensus Healthcare Price Performance

SRTS traded down $2.73 on Thursday, reaching $6.26. The company’s stock had a trading volume of 1,539,660 shares, compared to its average volume of 313,849. Sensus Healthcare has a 1 year low of $2.91 and a 1 year high of $9.33. The business’s 50 day moving average is $7.49 and its 200 day moving average is $6.89. The stock has a market cap of $102.60 million, a price-to-earnings ratio of 10.95 and a beta of 1.24.

Analysts Set New Price Targets

Several equities research analysts recently commented on SRTS shares. HC Wainwright raised their target price on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, November 18th. Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Lake Street Capital began coverage on shares of Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 target price for the company.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.